{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:25:01Z","timestamp":1783376701928,"version":"3.54.6"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK and Vir Biotechnology, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40264-024-01439-z","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T09:01:36Z","timestamp":1715331696000},"page":"843-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6293-3429","authenticated-orcid":false,"given":"Diego F.","family":"Wyszynski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4665-279X","authenticated-orcid":false,"given":"Lydia","family":"Demetriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-1653","authenticated-orcid":false,"given":"Cheryl","family":"Renz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3611-7377","authenticated-orcid":false,"given":"Shirin","family":"Aliabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8133-5172","authenticated-orcid":false,"given":"Dragutin","family":"Rafailovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4781-0866","authenticated-orcid":false,"given":"Lee P.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8994-2816","authenticated-orcid":false,"given":"Myriam","family":"Drysdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5177-1759","authenticated-orcid":false,"given":"Keele E.","family":"Wurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"1439_CR1","doi-asserted-by":"publisher","first-page":"E1129","DOI":"10.1503\/cmaj.202391","volume":"193","author":"A Pham-Huy","year":"2021","unstructured":"Pham-Huy A, Top KA, Constantinescu C, Seow CH, El-Cha\u00e2r D. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ. 2021;193:E1129\u201336.","journal-title":"CMAJ"},{"key":"1439_CR2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ajog.2021.08.025","volume":"225","author":"JS Hirshberg","year":"2021","unstructured":"Hirshberg JS, Cooke E, Oakes MC, Odibo AO, Raghuraman N, Kelly JC. Monoclonal antibody treatment of symptomatic COVID-19 in pregnancy: initial report. Am J Obstet Gynecol. 2021;225:688\u20139.","journal-title":"Am J Obstet Gynecol"},{"key":"1439_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/diagnostics10080583","volume":"10","author":"AM Ciobanu","year":"2020","unstructured":"Ciobanu AM, Dumitru AE, Gica N, Botezatu R, Peltecu G, Panaitescu AM. Benefits and risks of IgG transplacental transfer. Diagnostics (Basel). 2020;10:583.","journal-title":"Diagnostics (Basel)."},{"key":"1439_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12879-023-08198-9","volume":"23","author":"JJ Tuan","year":"2023","unstructured":"Tuan JJ, Sharma M, Kayani J, Davis MW, McManus D, Topal JE, et al. Outcomes of pregnant women exposed to sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO). BMC Infect Dis. 2023;23:258.","journal-title":"BMC Infect Dis"},{"key":"1439_CR5","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.09.434607","author":"AL Cathcart","year":"2022","unstructured":"Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid MA, Agostini ML, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2022. https:\/\/doi.org\/10.1101\/2021.03.09.434607.","journal-title":"bioRxiv."},{"key":"1439_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002493","volume":"15","author":"MR Gaudinski","year":"2018","unstructured":"Gaudinski MR, Coates EE, Houser KV, Chen GL, Yamshchikov G, Saunders JG, et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018;15: e1002493.","journal-title":"PLoS Med"},{"key":"1439_CR7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nature13612","volume":"514","author":"SY Ko","year":"2014","unstructured":"Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014;514:642\u20135.","journal-title":"Nature"},{"key":"1439_CR8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290\u20135.","journal-title":"Nature"},{"key":"1439_CR9","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941\u201350.","journal-title":"N Engl J Med"},{"key":"1439_CR10","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jama.2022.2832","volume":"327","author":"A Gupta","year":"2022","unstructured":"Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Rodrigues Falci D, et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327:1236\u201346.","journal-title":"JAMA"},{"key":"1439_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.idc.2022.01.002","volume":"36","author":"SA Rasmussen","year":"2022","unstructured":"Rasmussen SA, Jamieson DJ. COVID-19 and pregnancy. Infect Dis Clin North Am. 2022;36:423\u201333.","journal-title":"Infect Dis Clin North Am"},{"key":"1439_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ajog.2021.08.054","volume":"226","author":"DJ Jamieson","year":"2022","unstructured":"Jamieson DJ, Rasmussen SA. An update on COVID-19 and pregnancy. Am J Obstet Gynecol. 2022;226:177\u201386.","journal-title":"Am J Obstet Gynecol"},{"key":"1439_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3320","volume":"370","author":"J Allotey","year":"2020","unstructured":"Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370: m3320.","journal-title":"BMJ"},{"key":"1439_CR14","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.15585\/mmwr.mm6944e3","volume":"69","author":"LD Zambrano","year":"2020","unstructured":"Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status\u2014United States, January 22\u2013October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1641\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1439_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40265-022-01690-7","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA. Sotrovimab: first approval. Drugs. 2022;82:477\u201384.","journal-title":"Drugs"},{"issue":"3","key":"1439_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40264-023-01377-2","volume":"47","author":"DF Wyszynski","year":"2024","unstructured":"Wyszynski DF, Papageorghiou AT, Renz C, Metz TD, Hern\u00e1ndez-D\u00edaz S. The COVID-19 International Drug Pregnancy Registry (COVID-PR): protocol considerations. Drug Saf. 2024;47(3):195\u2013204. https:\/\/doi.org\/10.1007\/s40264-023-01377-2.","journal-title":"Drug Saf"},{"key":"1439_CR17","unstructured":"European Medicines Agency. Xevudy summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xevudy-epar-product-information_en.pdf. Accessed 2 Nov 2023."},{"key":"1439_CR18","unstructured":"US FDA. Guidance for industry: establishing pregnancy exposure registries. 2002. https:\/\/www.fda.gov\/media\/75607\/download. Accessed 10 Oct 2023."},{"key":"1439_CR19","unstructured":"European Medicines Agency. Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data. 2005. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-exposure-medicinal-products-during-pregnancy-need-post-authorisation-data_en.pdf. Accessed 2 Nov 2023."},{"key":"1439_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/(SICI)1099-1557(199609)5:5<333::AID-PDS244>3.0.CO;2-5","volume":"5","author":"EA Andrews","year":"1996","unstructured":"Andrews EA, Avorn J, Bortnichak EA, Chen R, Dai WS, Dieck GS, et al. Guidelines for Good Epidemiology Practices for drug, device, and vaccine research in the United States. Pharmacoepidemiol Drug Saf. 1996;5:333\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1439_CR21","unstructured":"European Medicines Agency. Good pharmacovigilance practices. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/good-pharmacovigilance-practices. Accessed 20 Oct 2023."},{"key":"1439_CR22","unstructured":"US FDA. Postapproval pregnancy safety studies: guidance for industry. 2019. https:\/\/www.fda.gov\/media\/124746\/download. Accessed 10 Oct 2023."},{"key":"1439_CR23","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"1439_CR24","unstructured":"Centers for Disease Control and Prevention. Metropolitan Atlanta Congenital Defects Program. https:\/\/www.cdc.gov\/ncbddd\/birthdefects\/macdp.html. Accessed 9 Apr 2024."},{"key":"1439_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40121-022-00755-0","volume":"12","author":"MM Cheng","year":"2023","unstructured":"Cheng MM, Reyes C, Satram S, Birch H, Gibbons DC, Drysdale M, et al. Real-world effectiveness of sotrovimab for the early treatment of COVID-19 during SARS-CoV-2 Delta and Omicron waves in the USA. Infect Dis Ther. 2023;12:607\u201321.","journal-title":"Infect Dis Ther"},{"key":"1439_CR26","doi-asserted-by":"publisher","DOI":"10.1101\/2022.11.28.22282808","author":"V Patel","year":"2022","unstructured":"Patel V, Yarwood MJ, Levick B, Gibbons DC, Drysdale M, Kerr W, et al. Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England. medRxiv. 2022. https:\/\/doi.org\/10.1101\/2022.11.28.22282808.","journal-title":"medRxiv."},{"key":"1439_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13223-022-00730-x","volume":"18","author":"B Aberumand","year":"2022","unstructured":"Aberumand B, Kamal R, McKinney B, Betschel S. Monoclonal antibody treatment of COVID-19 in a pregnant woman with common variable immunodeficiency. Allergy Asthma Clin Immunol. 2022;18:91.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1439_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/jama.2022.0335","volume":"327","author":"RT Gandhi","year":"2022","unstructured":"Gandhi RT, Malani PN, Del Rio C. COVID-19 therapeutics for nonhospitalized patients. JAMA. 2022;327:617\u20138.","journal-title":"JAMA"},{"key":"1439_CR29","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.7326\/M22-1329","volume":"175","author":"EK McCreary","year":"2022","unstructured":"McCreary EK, Lemon L, Megli C, Oakes A, Seymour CW, UPMC Magee Monoclonal Antibody Treatment Group. Monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy: a cohort study. Ann Intern Med. 2022;175:1707\u201315.","journal-title":"Ann Intern Med"},{"key":"1439_CR30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/AOG.0000000000004689","volume":"139","author":"M Richley","year":"2022","unstructured":"Richley M, Rao RR, Afshar Y, Mei J, Mok T, Vijayan T, et al. Neutralizing monoclonal antibodies for coronavirus disease 2019 (COVID-19) in pregnancy: a case series. Obstet Gynecol. 2022;139:368\u201372.","journal-title":"Obstet Gynecol"},{"key":"1439_CR31","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/AOG.0000000000004700","volume":"139","author":"BP Thilagar","year":"2022","unstructured":"Thilagar BP, Ghosh AK, Nguyen J, Theiler RN, Wick MJ, Hurt RT, et al. Anti-spike monoclonal antibody therapy in pregnant women with mild-to-moderate coronavirus disease 2019 (COVID-19). Obstet Gynecol. 2022;139:616\u20138.","journal-title":"Obstet Gynecol"},{"key":"1439_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.5582\/ddt.2022.01036","volume":"16","author":"T Izumo","year":"2022","unstructured":"Izumo T, Awano N, Kuse N, Sakamoto K, Takada K, Muto Y, et al. Efficacy and safety of sotrovimab for vaccinated or unvaccinated patients with mild-to-moderate COVID-19 in the omicron era. Drug Discov Ther. 2022;16:124\u20137.","journal-title":"Drug Discov Ther."},{"key":"1439_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijid.2022.09.023","volume":"124","author":"A Zaqout","year":"2022","unstructured":"Zaqout A, Almaslamani MA, Chemaitelly H, Hashim SA, Ittaman A, Alimam A, et al. Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar. Int J Infect Dis. 2022;124:96\u2013103.","journal-title":"Int J Infect Dis"},{"key":"1439_CR34","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1097\/TP.0000000000004083","volume":"106","author":"F AlKindi","year":"2022","unstructured":"AlKindi F, Chaaban A, Al Hakim M, Boobes Y. Sotrovimab use for COVID-19 infection in pregnant kidney transplant recipient. Transplantation. 2022;106:e277\u20138.","journal-title":"Transplantation"},{"key":"1439_CR35","volume":"14","author":"I Gupta","year":"2022","unstructured":"Gupta I, Arguello Perez ES. Use of sotrovimab in a pregnant patient with COVID-19 infection. Cureus. 2022;14: e22658.","journal-title":"Cureus."},{"key":"1439_CR36","unstructured":"Centers for Disease Control and Prevention. Genomic surveillance for SARS-CoV-2 variants: circulation of Omicron lineages\u2014United States, January 2022\u2013May 2023. 2023. https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/wr\/mm7224a2.htm#:~:text=Omicron%20remained%20predominant%20during%20January,%2C%202022%2C%20followed%20by%20BA. Accessed 10 Oct 2023."},{"key":"1439_CR37","doi-asserted-by":"publisher","first-page":"100410","DOI":"10.1016\/j.lanepe.2022.100410","volume":"18","author":"G Favre","year":"2022","unstructured":"Favre G, Maisonneuve E, Pomar L, Winterfeld U, Daire C, Martinez de Tejada B, et al. COVID-19 mRNA vaccine in pregnancy: results of the Swiss COVI-PREG registry, an observational prospective cohort study. Lancet Reg Health Eur. 2022;18:100410.","journal-title":"Lancet Reg Health Eur."},{"key":"1439_CR38","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/bdr2.2070","volume":"114","author":"S Hern\u00e1ndez-Di\u00e1z","year":"2022","unstructured":"Hern\u00e1ndez-Di\u00e1z S, Smith LH, Wyszynski DF, Rasmussen SA. First trimester COVID-19 and the risk of major congenital malformations-International Registry of Coronavirus Exposure in Pregnancy. Birth Defects Res. 2022;114:906\u201314.","journal-title":"Birth Defects Res"},{"key":"1439_CR39","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1016\/j.vaccine.2016.07.006","volume":"34","author":"J Bonhoeffer","year":"2016","unstructured":"Bonhoeffer J, Kochhar S, Hirschfeld S, Heath PT, Jones CE, Bauwens J, et al. Global alignment of immunization safety assessment in pregnancy\u2014the GAIA project. Vaccine. 2016;34:5993\u20137.","journal-title":"Vaccine"},{"key":"1439_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12963-017-0122-8","volume":"15","author":"DC McCoy","year":"2017","unstructured":"McCoy DC, Sudfeld CR, Bellinger DC, Muhihi A, Ashery G, Weary TE, et al. Development and validation of an early childhood development scale for use in low-resourced settings. Popul Health Metr. 2017;15:3.","journal-title":"Popul Health Metr"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01439-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01439-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01439-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T14:24:39Z","timestamp":1723645479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01439-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1439"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01439-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"22 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The COVID-PR receives funding from Gilead Sciences, GSK\/Vir Biotechnology, Inc., MSD, and Roche. This study (216978) was funded by GSK and Vir Biotechnology, Inc. The open access fee for this paper was funded by GSK and Vir Biotechnology, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Diego F. Wyszynski, Cheryl Renz, and Dragutin Rafailovic are employees of Pregistry, a company contracted by GSK and others (see the Funding statement above) to conduct the COVID-PR. Lydia Demetriou, Shirin Aliabadi, Myriam Drysdale, and Keele E. Wurst are employees of GSK and hold shares in the company. Lee P. Shulman has no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study protocol has been approved in the United States by the WCG IRB (20214420), in Japan by the Medical Corporation TOUKEIKAI Kitamachi Clinic ERB (RVG0947720230315), and in Australia by the Bellberry Human Research Ethics Committee (2022-04-403). Clearance that approval is not required to conduct the study has been given by Ethics Committees in the following countries: Bulgaria, Canada, Croatia, Czech Republic, Denmark, Germany, Greece, Hong Kong, Italy, Malaysia, New Zealand, Poland, Romania, Singapore, South Africa, South Korea, and the United Kingdom. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Eligible subjects signed an electronic consent form prior to enrolling in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation"}},{"value":"Participants provided informed written consent before taking part in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This manuscript has no associated data or the data will not be deposited. The COVID-PR study protocol may be made available by the corresponding author on reasonable request, following applicable regulations.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The original study protocol was designed by Diego F. Wyszynski, who planned the study, designed the study methodology, supervised data collection and data verification, and drafted the first version of the article. Lydia Demetriou, Cheryl Renz, Shirin Aliabadi, Dragutin Rafailovic, Lee P. Shulman, Myriam Drysdale, and Keele E. Wurst provided advice on the study methodology and edited the first and final versions of the article. All authors have read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}